20/20 Biolabs, INC

Market Movers (8-K)

NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Enters Standstill with Investor, Faces Nasdaq Bid Price Concern
20/20 Biolabs, Inc. has entered into a 120-day standstill agreement with Streeterville Capital, LLC, while also receiving a notice from Nasdaq regarding non-compliance with the minimum bid price rule.
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Investor Webinar: Medicare Reimbursement Pathway
20/20 Biolabs presented its OneTest multi-cancer early detection (MCED) test, highlighting a potential Medicare reimbursement pathway established by recent legislation and contrasting its approach with ctDNA-based tests.